Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) EBIT (2019 - 2025)

Historic EBIT for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to -$9.8 million.

  • Benitec Biopharma's EBIT fell 7725.31% to -$9.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$41.8 million, marking a year-over-year decrease of 8570.48%. This contributed to the annual value of -$41.8 million for FY2025, which is 8570.48% down from last year.
  • Benitec Biopharma's EBIT amounted to -$9.8 million in Q2 2025, which was down 7725.31% from -$15.3 million recorded in Q1 2025.
  • Benitec Biopharma's 5-year EBIT high stood at -$3.5 million for Q1 2022, and its period low was -$15.3 million during Q1 2025.
  • Moreover, its 5-year median value for EBIT was -$4.8 million (2021), whereas its average is -$6.0 million.
  • Per our database at Business Quant, Benitec Biopharma's EBIT surged by 877.93% in 2022 and then plummeted by 27032.12% in 2025.
  • Over the past 5 years, Benitec Biopharma's EBIT (Quarter) stood at -$4.8 million in 2021, then decreased by 16.03% to -$5.6 million in 2022, then decreased by 23.48% to -$6.9 million in 2023, then tumbled by 55.98% to -$10.8 million in 2024, then increased by 8.99% to -$9.8 million in 2025.
  • Its EBIT was -$9.8 million in Q2 2025, compared to -$15.3 million in Q1 2025 and -$10.8 million in Q4 2024.